Antimitotic Inhibitors
Of the agents available in the treatment of both solid and hematologic cancers, microtubule-targeted agents are among the most widely used and exploiting other mechanisms involving the microtubule and its…
Tyrosine Kinase Inhibitors in Lung Cancer
Identification of driver mutations in growth related protein kinases, especially tyrosine kinases, has led to clinical development of an array of tyrosine kinase inhibitors in various malignancies, including lung cancer….
Targeting the Hedgehog Pathway
The Hedgehog (Hh) pathway is a signaling cascade that is evolutionally highly conserved and plays an important role in embryonic pattern formation and stem cell response to tissue damage. Given…
Targeting Angiogenesis in Gynecologic Cancers
Gynecologic malignancies carry an estimated incidence of 83,750 cases per year and estimated mortality rate of more than 27,000 women per year. New therapies and therapeutic approaches are needed to…
Targeting the Insulin Growth Factor Receptor 1
The IGF axis is a tightly controlled endocrine system that regulates cell growth and development, known to have an important function in cancer biology. IGF1 and IGF2 can promote cancer…
Topoisomerase 1 Inhibitors and Cancer Therapy
Topoisomerase 1 inhibitors cure human cancer xenografts in animal models, more so than most other chemotherapy agents. However, their activity in patients with cancer is modest. Ongoing research is studying…
mTOR Signaling Pathway and mTOR Inhibitors in Cancer Therapy
Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase. It is ubiquitously expressed in cells and is a therapeutic target for the cancer treatment arsenal. Despite the great responses…
Therapeutic Antibodies Against Cancer
Antibody-based therapeutics against cancer are highly successful and currently enjoy unprecedented recognition of their potential; 13 monoclonal antibodies (mAbs) have been approved for clinical use in the European Union and…
Clinical Drug Development in 2012
Franco Muggia, MD, Guest Editor Hosting as editor this 2012 issue of Hematology Oncology Clinics of North America is an opportunity to reflect on trends in clinical drug development. In…
Management of Brain Metastases
A significant number of cancer patients will develop intracranial metastases. In general, treatment of these lesions uses a combination of surgery and radiation. However, over the past several decades the…
